Roanna Ruiz
Stock Analyst at Leerink Partners
(0.74)
# 3,955
Out of 5,072 analysts
59
Total ratings
30.77%
Success rate
-18.03%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.20 | +66.67% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $7.18 | +25.35% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.59 | +340.25% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $9.65 | +86.53% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.43 | -30.07% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $6.39 | +212.99% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.57 | +182.13% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $6.22 | +109.00% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.93 | +136.09% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $488.43 | -32.44% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $68.15 | -14.89% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $79.80 | -68.67% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.93 | +251.83% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.05 | +96.72% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $41.45 | -54.16% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $58.75 | +104.26% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $9.86 | +407.10% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $16.14 | +147.83% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.20
Upside: +66.67%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $7.18
Upside: +25.35%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.59
Upside: +340.25%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $9.65
Upside: +86.53%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.43
Upside: -30.07%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.39
Upside: +212.99%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.57
Upside: +182.13%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $6.22
Upside: +109.00%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.93
Upside: +136.09%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $488.43
Upside: -32.44%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $68.15
Upside: -14.89%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $79.80
Upside: -68.67%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.93
Upside: +251.83%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.05
Upside: +96.72%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $41.45
Upside: -54.16%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $58.75
Upside: +104.26%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $9.86
Upside: +407.10%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $16.14
Upside: +147.83%